|
C9ORF46 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.28259625142846E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.0244000031866E-08 |
| Normal-vs-Stage2 |
9.766900E-04 |
| Normal-vs-Stage3 |
4.87139999449937E-08 |
| Normal-vs-Stage4 |
3.627600E-04 |
| Stage1-vs-Stage2 |
3.247000E-01 |
| Stage1-vs-Stage3 |
2.625800E-01 |
| Stage1-vs-Stage4 |
3.609600E-01 |
| Stage2-vs-Stage3 |
7.429200E-01 |
| Stage2-vs-Stage4 |
8.238200E-01 |
| Stage3-vs-Stage4 |
9.325000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.85570003807811E-09 |
| Normal-vs-AfricanAmerican |
1.816150E-02 |
| Normal-vs-Asian |
7.720000E-03 |
| Caucasian-vs-AfricanAmerican |
8.177000E-01 |
| Caucasian-vs-Asian |
4.563200E-01 |
| AfricanAmerican-vs-Asian |
4.876000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.25369999995451E-06 |
| Normal-vs-Female |
3.8301029015031E-11 |
| Male-vs-Female |
5.627400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.53169999997471E-06 |
| Normal-vs-Age(41-60Yrs) |
1.05909999992271E-07 |
| Normal-vs-Age(61-80Yrs) |
5.10039999124245E-09 |
| Normal-vs-Age(81-100Yrs) |
4.442000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.415400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.171860E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.245400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.160400E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.480000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.168590E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.384080E-02 |
| Classical-VS-Follicular |
5.983000E-04 |
| Classical-VS-Other |
3.862200E-01 |
| Classical-VS-Normal |
1.67819999996599E-06 |
| Tall-VS-Follicular |
8.858600E-01 |
| Tall-VS-Other |
3.646500E-02 |
| Tall-VS-Normal |
4.96390000004343E-06 |
| Follicular-VS-Other |
7.472200E-02 |
| Follicular-VS-Normal |
2.48130005431335E-09 |
| Other-VS-Normal |
6.960600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.68520033669995E-10 |
| Normal-vs-N1 |
3.079600E-02 |
| N0-vs-N1 |
8.060200E-02 |
|
|
